TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Ireland > How is Brexit impacting Pharma ?

How is Brexit impacting Pharma ?

The UK Government has published a series of technical notices that provide guidance to the industry.  The “no deal” scenario is one where the UK leaves the EU and becomes a third country at 11pm GMT on 29th March 2019 without a Withdrawal Agreement being in place between the UK and the EU. The guidance documents do stress that the UK government is working to agree a trade deal with the EU and the position set out in the notices are only applicable in the “unlikely scenario that they need to be relied upon”. However, the EMA has published on its website that it is “working on the scenario that the UK will become a third country” as of the above exit date.

A total of 25 notices were published as part of a series in August and September 2018 to allow businesses and citizens prepare. Several guidance documents relevant to the pharmaceutical industry have been published and require careful consideration from the industry. The series of notices include the documents listed below that are particularly relevant to the pharmaceutical sector:

  • Batch testing medicines if there’s no Brexit deal
  • Ensuring blood and blood products are safe if there’s no Brexit deal
  • How medicines, medical devices and clinical trials would be regulated if there’s no Brexit deal
  • Quality and safety of organs, tissues and cells if there’s no Brexit deal
  • Submitting regulatory information on medical products if there’s no Brexit deal
  • Trading in drug precursors if there’s no Brexit deal

So what are the implications of such a scenario? Some of the key points in the guidance documents include:

  • All centrally authorised medicinal products will automatically be converted into national UK marketing authorisations (MA) on 29th Mar 2019.
  • Applications (i.e. centralised, decentralised and mutual recognition procedure) in progress on exit day will not be valid in the UK and will continue to be assessed by the MHRA as National Procedures.
  • Future MA submissions will have to be submitted into both MHRA and EMA. The new process will be streamlined with the intention to issue the UK MA and the EU MA concurrently.
  • New generic applications would need to be based on reference products that have been authorised in the UK.
  • A UK based MA holder will need to be established in the UK by the end of 2020
  • The Qualified Person for Pharmacovigilance (QPPV) should be established in the UK by the end of 2020. However, from exit day, the MHRA should have access to the relevant safety data from the EU QPPV.
  • With respect to medical devices, the UK will, for a limited period, continue to recognise the CE mark so devices will be accepted on the UK market if they meet EU requirements. The MHRA, however, will no longer be able to oversee Notified Bodies.
  • UK clinical trial applications will continue to be authorised by the MHRA. However, Clinical Trial Regulation 536/2014 planned for implementation in 2019 will not be in effect in the EU when the UK exits the EU.
  • The UK will continue to accept batch testing of human medicines and investigational medicinal products carried out in countries on a list created by the MHRA. The UK will also require a UK, EU or EEA-based QP to certify batch release and to assure compliance with the marketing authorisation.
  • The UK would no longer be part of the EMA regulatory network shared processes which would result in the requirement for regulatory information relating to human medicines and devices to be submitted directly to the MHRA. In addition, the UK would no longer be part of the EU system for sharing pharmacovigilance information which would mean that the MHRA will take on the primary responsibility to oversee pharmacovigilance activities relating to UK MAs and UK MAHs would have to submit PV data directly to the MHRA.
  • Public consultation is proposed on other areas including Orphan medicinal products, paediatric medicines and medical devices
  • The current EU Blood Directives would no longer apply to the UK and arrangements for sharing blood, blood components and information with EU partners would be based on the UK’s status as a third country.

The UK government’s guidance documents are very welcomed by the industry as they provide some clarity as to the no deal scenario. Make sure you give them the careful consideration they require!

If you would like our Brexit Taskforce Team to examine your Brexit-preparedness strategy and tactical action plan, please connect with us to discuss +353 1 846 4742 or  contactirl@pharmalex.com

Related posts
Why collaboration and an Integrated Product Development program are key to successful drug development
Why collaboration and an Integrated Product Development program are key to successful drug development
14th June 2022
Key Takeaways from the PDA Europe Annex 1 Workshop
Key Takeaways from the PDA Europe Annex 1 Workshop
7th June 2022
NLS DAYS 2022
NLS DAYS 2022
September 28 - May 29th, 2022
Addressing Limitations of Sterility Testing
Addressing Limitations of Sterility Testing
9th May 2022
Are virtual audits sustainable post-pandemic?
Are virtual audits sustainable post-pandemic?
6th May 2022
Orphan Drug Designation: Securing the Significant Benefits
Orphan Drug Designation: Securing the Significant Benefits
28th March 2022
Search
Upcoming Webinars

June 28th, 2022

eCTD in Australia: key steps to start a successful submission

08:30 am CET / 4:30 pm AEST

June 28th, 2022

An Introduction to Bayesian adaptive methods in clinical trials

04:00 PM CET

June 30th, 2022

Transforming the drug development process with an integrated strategy

03:00 PM CET

Categories
  • All News
  • Webinars
  • Events
Archive
Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
24 Jun

Milena Shuytsova-Mircheva and Lisa Pascoe latest blog here https://www.pharmalex.com/sponsors-gear-up-for-a-smoother-process-with-ctis-but-must-first-overcome-key-hurdles/ discusses the benefit of the Clinical Trial Information System (CTIS).

💡 Interested in CTIS? Take the Phlexglobal survey to evaluate your preparation https://www.phlexglobal.com/ctis-survey

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • We needed a partner to help us obtain device approval. PharmaLex have not only helped us achieve this but are now providing on-going post-marketing surveillance support. We would highly recommend them to anyone who needs specialist expertise.

    Med Device company, US
    Senior Regulatory Affairs Director
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.






    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for